Digestive Disease Center, Showa University Northern Yokohama Hospital, Kanagawa, Japan.
Clinical Effectiveness Research Group, University of Oslo, Oslo, Norway.
Dig Endosc. 2022 Jul;34(5):1030-1039. doi: 10.1111/den.14202. Epub 2021 Dec 12.
Complete endoscopic healing, defined as Mayo endoscopic score (MES) = 0, is an optimal target in the treatment of ulcerative colitis (UC). However, some patients with MES = 0 show clinical relapse within 12 months. Histologic goblet mucin depletion has emerged as a predictor of clinical relapse in patients with MES = 0. We observed goblet depletion in vivo using an endocytoscope, and analyzed the association between goblet appearance and future prognosis in UC patients.
In this retrospective cohort study, all enrolled UC patients had MES = 0 and confirmed clinical remission between October 2016 and March 2020. We classified the patients into two groups according to the goblet appearance status: preserved-goblet and depleted-goblet groups. We followed the patients until March 2021 and evaluated the difference in cumulative clinical relapse rates between the two groups.
We identified 125 patients with MES = 0 as the study subjects. Five patients were subsequently excluded. Thus, we analyzed the data for 120 patients, of whom 39 were classified as the preserved-goblet group and 81 as the depleted-goblet group. The patients were followed-up for a median of 549 days. During follow-up, the depleted-goblet group had a significantly higher cumulative clinical relapse rate than the preserved-goblet group (19% [15/81] vs. 5% [2/39], respectively; P = 0.02).
Observing goblet appearance in vivo allowed us to better predict the future prognosis of UC patients with MES = 0. This approach may assist clinicians with onsite decision-making regarding treatment interventions without a biopsy.
内镜下完全愈合(定义为 Mayo 内镜评分[MES]=0)是溃疡性结肠炎(UC)治疗的理想目标。然而,一些 MES=0 的患者在 12 个月内出现临床复发。组织学杯状黏液缺失已成为 MES=0 患者临床复发的预测指标。我们使用内镜内细胞仪观察到体内杯状细胞缺失,并分析了 UC 患者杯状细胞外观与未来预后之间的关系。
在这项回顾性队列研究中,所有入组的 UC 患者 MES=0,且在 2016 年 10 月至 2020 年 3 月间确认临床缓解。我们根据杯状细胞外观状态将患者分为两组:保留杯状细胞组和缺失杯状细胞组。我们随访患者至 2021 年 3 月,评估两组累积临床复发率的差异。
我们确定了 125 名 MES=0 的患者作为研究对象。随后排除了 5 名患者。因此,我们分析了 120 名患者的数据,其中 39 名患者被归类为保留杯状细胞组,81 名患者被归类为缺失杯状细胞组。患者中位随访时间为 549 天。随访期间,缺失杯状细胞组的累积临床复发率明显高于保留杯状细胞组(分别为 19%[15/81]和 5%[2/39];P=0.02)。
在体内观察杯状细胞外观可以更好地预测 MES=0 的 UC 患者的未来预后。这种方法可以帮助临床医生在不进行活检的情况下,对治疗干预进行现场决策。